Patent Assignment
Reel/Frame 045395/0590
Merger
Recorded: 2018-03-30
Pages: 4
Assignor
TRUBION PHARMACEUTICALS
Executed: 2010-10-28
Assignee
EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC
2401 FOURTH AVENUE, SUITE 1050, SEATTLE, WASHINGTON, 98121
Covered Property
(1)
B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
Related Assignments
(4)
Other recorded transfers of the patent in this record — the chain of ownership.
Change of Name
Jul 18, 2016
From: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC
To: APTEVO RESEARCH AND DEVELOPMENT LLC
Reel/Frame 039382/0985 →
Assignment of Assignor's Interest
Mar 30, 2018
From: GROSMAIRE, LAURA S.; HAYDEN-LEDBETTER, MARTHA S.; LEDBETTER, JEFFREY A.; THOMPSON, PETER A.
To: TRUBION PHARMACEUTICALS
Reel/Frame 045395/0584 →
Security Interest
Feb 7, 2019
From: APTEVO THERAPEUTICS INC.; APTEVO BIOTHERAPEUTICS INC.; APTEVO RESEARCH AND DEVELOPMENT LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 048270/0813 →
Release of Security Interest
Mar 6, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: APTEVO THEAPEUTICS INC.; APTEVO BIOTHERAPEUTICS LLC; APTEVO RESEARCH AND DEVELOPMENT LLC
Reel/Frame 052039/0258 →